Written Communication Relating to an Issuer or Third Party (sc To-c)
02 Noviembre 2017 - 5:14AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE TO
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
Ocera
Therapeutics, Inc.
(Name of Subject Company)
MEH
ACQUISITION CO.
(Offeror)
A Wholly Owned Subsidiary of
MAK LLC
(Parent of
Offeror)
A Wholly Owned Subsidiary of
MALLINCKRODT PUBLIC LIMITED COMPANY
(Parent of Offeror)
(Names of Filing Persons)
Common Stock, par value $0.00001 per share
(Title of Class of Securities)
67552A108
(CUSIP Number
of Class of Securities)
Michael-Bryant Hicks, Esq.
General Counsel
Mallinckrodt
675 James
S. McDonnell Blvd.
Hazelwood, Missouri 63042 USA
(314)
654-2000
(Name, address, and telephone number of person authorized to receive notices and communications on behalf of filing persons)
with copies to:
Stephanie M. Hosler, Esq.
Brian K. Feezel, Esq.
Bryan Cave LLP
211 N.
Broadway
One Metropolitan Square, Suite 3600
St. Louis, Missouri 63102
(314)
259-2000
CALCULATION
OF FILING FEE
|
|
|
|
|
Transaction Valuation
|
|
Amount of Filing Fee*
|
|
Not Applicable
|
|
Not Applicable
|
|
|
|
*
|
A filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of a tender offer.
|
|
☐
|
Check the box if any part of the fee is offset as provided by Rule
0-11(a)(2)
and identify the filing with which the offsetting fee was previously paid. Identify the previous
filing by registration statement number, or the Form or Schedule and the date of its filing.
|
|
|
|
|
|
Amount Previously Paid: N/A
|
|
Filing Party: N/A
|
|
Form or Registration No.: N/A
|
|
Date Filed: N/A
|
|
☒
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
Check the appropriate boxes below to designate any transactions to which the statement relates:
|
|
☒
|
third-party tender offer subject to Rule
14d-1.
|
|
|
☐
|
issuer tender offer subject to Rule
13e-4.
|
|
|
☐
|
going-private transaction subject to Rule
13e-3.
|
|
|
☐
|
amendment to Schedule 13D under Rule
13d-2.
|
Check the
following box if the filing is a final amendment reporting the results of the tender offer:
☐
If applicable,
check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
|
|
☐
|
Rule
13e-4(i)
(Cross-Border Issuer Tender Offer)
|
|
|
☐
|
Rule
14d-1(d)
(Cross-Border Third-Party Tender Offer)
|
This filing relates solely to preliminary communications made before the commencement of a tender offer by MEH
Acquisition Co., a Delaware corporation (“Purchaser”) and an indirect wholly owned subsidiary of Mallinckrodt plc, an Irish public limited company (“Mallinckrodt”), to purchase all of the shares of common stock, par value
$0.00001 per share, of Ocera Therapeutics, Inc., a Delaware corporation (“Ocera Therapeutics”), that are issued and outstanding, pursuant to an Agreement and Plan of Merger, dated as of November 1, 2017, by and among Purchaser, MAK
LLC, Mallinckrodt and Ocera Therapeutics.
Additional Information and Notice to Investors
This communication is for informational purposes only and does not constitute an offer to purchase nor a solicitation of an offer to sell any securities of
Ocera Therapeutics. The tender offer for the shares of Ocera Therapeutics common stock described in this communication has not yet commenced. The solicitation and offer to purchase shares of Ocera Therapeutics common stock will only be made pursuant
to a tender offer statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal, and other related documents. Upon commencement of the tender offer, Mallinckrodt plc and its wholly-owned subsidiaries, MAK LLC
and MEH Acquisition Co., will file with the SEC a tender offer statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal, and other related documents. In addition, Ocera will file with the SEC a tender
offer solicitation/recommendation statement on Schedule
14D-9
with respect to the tender offer. These documents will contain important information, including the terms and conditions of the tender offer.
Investors and security holders are urged to read each of these documents and any amendments to these documents carefully when they are available prior to making any decisions with respect to the tender offer. Investors and security holders will be
able to obtain free copies of these materials (when available) and other documents filed with the SEC through the web site maintained by the SEC at www.sec.gov. Copies of the documents filed by Mallinckrodt plc, MAK LLC and MEH Acquisition Co. with
the SEC will also be available free of charge on the Investor Relations section of our website at www.mallinckrodt.com and copies of the documents filed by Ocera with the SEC will be available free of charge on Ocera’s website at ocerainc.com.
2
EXHIBIT INDEX
3
Ocera Therapeutics, Inc. (NASDAQ:OCRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Ocera Therapeutics, Inc. (NASDAQ:OCRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
